Imeglimin

Imeglimin is an experimental drug being developed as an oral anti-diabetic.[1] It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.

Imeglimin
Names
Preferred IUPAC name
(2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
UNII
InChI
  • InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
    Key: GFICWFZTBXUVIG-SCSAIBSYSA-N
  • InChI=1/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
    Key: GFICWFZTBXUVIG-SCSAIBSYBC
SMILES
  • C[C@H]1NC(=NC(=N1)N)N(C)C
Properties
Chemical formula
 C6H13N5
Molar mass 155.205 g·mol−1
Pharmacology
None
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

References
  1. Vuylsteke, V; Chastain, L. M; Maggu, G. A; Brown, C (2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–232. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.